Dr. Zhang brings to Biosion over 25 years of biopharmaceutical experience in the clinical development strategy and operations of oncology drug programs in China and APAC region. She successfully led key clinical development aspects of a number of innovative oncology assets, including a PD-1 mAb, PARP inhibitor and BRAF inhibitor, amongst others into markets.

Prior to joining Biosion, Dr. Zhang was Clinical Development Director, APAC, and Country Medical Director at Pierre Fabre Medicament. Before Pierre Fabre, Dr. Zhang was the Chief Medical Officer for Quintiles in the Greater China region. She helped to build the organization from 120 employees to 2,100 employees and built a new local subsidiary (Kuntuo). She led the Center of Clinical Excellence team to provide medical & scientific input for more than 30 due diligence licensing efforts to help local and global pharmaceutical companies develop and register products in the Greater China region.

Dr. Zhang holds a M.D. in Clinical Medicine from Shanghai Jiao Tong University in China, and a M.B.A. from Cardiff University in the United Kingdom.